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Tumour recurrence and metastases of hepatocellular carcinoma (HCC) after hepatectomy are the major obstacles of long-term
survival. The present study investigated the clinicopathological significance of a possible metastasis regulator Six1 in HCC patients
who were undergone hepatectomy. Seventy-two pairs of RNA and 103 pairs of protein from tumour and adjacent nontumour liver
tissues of HCC patients were examined. About 85 and 60% of HCC tumour tissues were found to overexpress Six1 mRNA and
protein, respectively, compared with nontumour liver tissues. No Six1 protein was detected in HCC nontumour liver tissues and
normal liver tissues. Increased Six1 protein expression in HCC patients was significantly correlated with pathologic tumour-node-
metastasis (pTNM) stage (P¼ 0.002), venous infiltration (P¼ 0.004) and poor overall survival (P¼ 0.0423). We concluded that Six1
is frequently overexpressed in HCC patients and elevated Six1 protein in HCC patients may be an indication of advanced stage and
poor overall survival after hepatectomy.
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Hepatocellular carcinoma (HCC) is one of the most malignant
cancers in the world with estimated 350 000 new cases and nearly
one million deaths annually (Schafer and Sorrell, 1999; Okuda,
2000). Acceleration of hepatitis B virus and hepatitis C virus
infection resulted in increase of HCC incidence both in Europe and
the US (El-Serag and Mason, 1999; Bosch et al, 2004). Surgical
treatments in terms of hepatic resection and orthotopic liver
transplantation are the potentially curative treatments for HCC,
but the long-term disease-free survival remains unsatisfactory (Lo
and Fan 2004; Poon and Fan 2004). Tumour recurrence and
metastases are the major causes of death in HCC patients after
surgical treatments (Llovet et al, 2005), indicating the necessity of
developing new therapeutic strategies targeting at tumour
recurrence and metastases in HCC. So far, the molecular
mechanism governing these processes in HCC remains unclear;
hence continuous identification and characterisation of novel
metastasis-associated genes are indispensable.
Six1 belongs to a subfamily of the Six class of homeodomain-
containing transcription factors, which share a lysine within the
DNA-binding helix of the homeodomain (Oliver et al, 1995). The
functions of vertebrate Six1 are involved in diverse organ
developments of the brain, ear, eye, muscle and kidney (Relaix
and Buckingham, 1999; Laclef et al, 2003; Xu et al, 2003; Zheng
et al, 2003; Ozaki et al, 2004). Overexpression of Six1 occurs in a
large percentage of primary breast cancer and strongly correlates
with metastatic breast lesions (Ford et al, 1998). Six1 elevated in
breast cancer promotes tumour progression through direct
activation of Cyclin A1 (Coletta et al, 2004). Moreover, Six1 plays
a substantial role in regulating the metastatic ability of rhabdo-
myosarcoma (RMS) (Yu et al, 2004). The above evidences indicate
that Six1 may be a critical regulator of metastases in different
cancers. Up to now, there has been no research reporting its roles
in HCC. In this study, we provided the first evidence of Six1
expression in HCC patients and cell lines aiming to investigate its
clinicopathological significance in HCC.
MATERIALS AND METHODS
Cell lines
Nonmetastatic human HCC cell lines Hep3B, Huh7 and PLC were
purchased from the American Type Culture Collection (Manassas,
VA, USA), and metastatic human HCC cell lines MHCC97L and
MHCC97H were obtained from the Liver Cancer Institute and
Zhongshan Hospital of Fudan University, Shanghai, the People’s of
Republic of China (Li et al, 2001). All cells were cultured in DMEM
high glucose medium with 10% FBS (Gibco, Grand Island, NY,
USA) and 1% penicilium and streptomycin at humidified 371C
incubator supplied with 5% CO2.
Clinical samples
One hundred and three HCC patients undergone liver resection
between March 1999 and June 2004 were recruited from
Department of Surgery, Queen Marry Hospital, the University of
Hong Kong, contributing to 103 pairs of protein extracts and 72
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pairs of RNA extracts from tumour tissues and adjacent
nontumour tissues. There were 87 men and 16 women. The age
of the patients ranged from 33– 75 years, with a median age of 55
years. Eighty-six HCC patients (83.5%) were positive for hepatitis
B surface antigen, whereas only three (2.9%) were positive for
hepatitis C virus antibody. Twenty normal liver tissues were
recruited from living donors at the same hospital. All donors were
examined to be free of liver diseases and hepatitis B infection. The
follow-up duration for the HCC patients ranged from July 1999 to
November 2005. The study was approved by the Ethics Committee
of the University of Hong Kong.
Reverse transcription – polymerase chain reaction
Total RNA from liver tissues and cell lines were extracted by
TRIZol regent according to the manufacturer’s instruction
(Invitrogen, Carlsbad, CA, USA). Each complementary DNA was
synthesised from 1 mg of RNA extract using the High capacity
cDNA Kit (Applied Biosystems, Foster City, CA, USA) under the
condition of 251C for 5 min following by 371C for 2 h. For clinical
samples, polymerase chain reaction (PCR) reaction for Six1 was
performed using the Taq PCR Kit (Promega, Madison, WI, USA)
under the following PCR cycles: 951C for 5 min, 40 cycles at 951C
for 1 min, 571C for 1 min and 721C for 1 min. For internal control
18S, 30 PCR cycles were used. For cell line samples, 30-cycle
multiplex PCR reaction was performed by combining Six1 and 18S
primers. Polymerase chain reaction products were visualised by
2% agarose gel electrophoresis stained with ethidium bromide.
Primers sets used were as follows: for Six1, sense 50 AAG GAG AAG
TCG AGG GGT GT-30, antisense 50-TGC TTG TTG GAG GAG GAG
TT-30; for 18S ribosomal RNA, sense 50-CTC TTA GCT GAG TGT
CCC GC-30, antisense 50-CTG ATC GTC TTC GAA CCT CC-30.
Western blot
Proteins from clinical specimens and HCC cell lines were prepared
by using Urea buffer (8 M Urea, pH 8.0). The amount of protein
lysates used for Western blot analysis was 100 mg and 50 mg for
clinical HCC samples and HCC cell lines, respectively. Protein
extracts were separated by 12% SDS–PAGE and transferred to
PDMF membrane (Millipore, Billerica, MA, USA) according to the
standard protocol. After blocking with 5% nonfat milk at room
temperature for 1 h, antibody with proper dilution was hybridised
with the membrane at 41C for overnight. The membrane was
washed three times with TBS/T each for 10 min and incubated with
secondary antibody at room temperature for 1 h. Protein signal
was detected by ECL Plus system (Amersham Biosciences,
Piscataway, NJ, USA). Antibodies Six1 and b-actin were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Statistical analysis
Statistical analysis was carried out using SPSS 11.5. for Windows
(SPSS Inc., Chicago, IL, USA). The association of Six1 protein
expression and clinicopathological parameters including sex, age,
tumour-node-metastasis (pTNM) staging, venous infiltration,
encapsulation, tumour size, alpha-fetoprotein level and hepatitis
B surface antigen was analysed by w2-test. The prognostic value of
Six1 protein for predicting the overall survival of HCC patients
after hepatic resection was calculated by Kaplan–Meier analysis
with the log-rank test. Cox proportional hazard regression model
was performed with univariable and multivariable analyses to test
factors that were significantly associated with the overall survival
of the HCC patients. Logistic regression analysis was also
performed to compare those factors for predicting 1- and 5-year
overall survival of the HCC patients. P valueo0.05 was considered
to be statistically significant.
RESULTS
Six1 expression in HCC cell lines
Three nonmetastatic HCC cell lines (Hep3B, Huh7 and PLC) and
two metastatic HCC cell lines (MHCC97L and MHCC97H) were
checked for Six1 gene expression in terms of mRNA and protein
levels (Figure 1). Using multiplex RT–PCR analysis, Six1 mRNA
was detected with a relatively higher level in Hep3B, MHCC97L
and MHCC97H comparing with the mRNA level in Huh7 and PLC.
The metastatic HCC cell line MHCC97H that is with the highest
metastatic potential expressed the highest level of Six1 mRNA.
Western blot analysis showed that Six1 protein was only expressed
in the metastatic cells and expressed the highest level in
MHCC97H.
Six1 expression in HCC patients and normal donors
Seventy-two pairs of tumour and nontumour liver tissues were
subjected for detection of Six1 mRNA by RT–PCR (Figure 2). A












Figure 1 Expression pattern of Six1 gene among nonmetastatic (Hep3B,
Huh7 and PLC) and metastatic (MHCC97L and MHCC97H) HCC cells.
Six1 mRNA was detected by RT–PCR and Six1 protein was detected by
Western blot analysis. Ribosomal RNA 18S and b-actin were internal
control for RT–PCR and Western blot, respectively.
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Figure 2 mRNA expression pattern of Six1 gene in HCC patients. RT–
PCR amplification was performed to exam the Six1 mRNA level in HCC
tumour tissues (T) and paired nontumour tissues (NT). Ribosomal RNA
18S was used as internal control.
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because Six1 mRNA in clinical samples could not be detected by
using multiplex PCR condition. Overexpression of Six1 mRNA was
found in about 85% (61 of 72) of tumour tissues compared with
nontumour tissues (Table 1). Most of the nontumour liver tissues
(91.7%) showed no Six1 mRNA expression. A few nontumour
tissues (six of 72) expressed Six1 mRNA but all the expression
levels were lower than those in the matched tumour tissues.
Western blot analysis showed that near 60% (61 of 103) of tumour
tissues expressed Six1 protein while no nontumour tissue
expressed Six1 protein (Figure 3, Table 1). Using w2-test with
Fisher’s exact test, Six1 mRNA overexpression in HCC patients was
significantly correlated with their Six1 protein overexpression
(P¼ 0.000, r¼ 0.438). All tumour tissues with positive Six1 protein
expression could match with their positive mRNA expression
except one case.
Reverse transcription –polymerase chain reaction and Western
blot were also used to analyse the Six1 mRNA and protein
expression patterns in normal liver tissues (Figure 4, Table 1).
Most of the normal liver tissues showed no Six1 mRNA expression
(90%), whereas only a few of them (two of 20) showed weak
positive signal. Moreover, no Six1 protein was expressed in normal
liver tissues.
Six1 protein expression correlated with advanced tumour
stage
Six1 protein expression pattern in HCC tumour tissues was
compared with their clinicopathological features (Table 2). Over-
expression of Six1 protein was significantly correlated with pTNM
stage (P¼ 0.002, r¼ 0.312) and venous infiltration (P¼ 0.004,
r¼ 0.282). Six1 protein expression was detected in 71% (45 of 63)
of advanced stage of HCC patients and in 71% (42 of 59) of HCC
patients with venous infiltration. No significant association was
found between Six1 protein and sex, age, cirrhosis, encapsulation,
tumour size, alpha-fetoprotein level or hepatitis B surface antigen.
Six1 protein expression correlated with poor survival
Kaplan–Meier analysis was employed to analyse the overall
survival rate of HCC patients in correspondence to the Six1
protein expression pattern. The result showed that HCC patients
who overexpressed Six1 protein were significantly associated with
poor overall survival (log rank¼ 4.12, P¼ 0.0423, Figure 5).
Kaplan–Meier analysis of pTNM staging, venous infiltration and
alpha-fetoprotein level also revealed to be significantly associated
with the overall survival of HCC patients (data not shown). To
further examine which factors were the independent predictors,
univariable and multivariable Cox proportional hazard regression
analyses of these factors corresponding to the overall survival of
HCC patients were performed. Univariable Cox proportional
hazard regression analysis showed that Six1 protein (HR¼ 1.956,
95% CI 1.011 –3.784, P¼ 0.046) and other factors were significantly
associated with the overall survival of HCC patients after hepatic
resection (Table 3). However, multivariable analysis indicated that
pTNM staging was the only independent factor for predicting the
overall survival of HCC patients (HR¼ 7.698, 95% CI 1.891–31.33,
P¼ 0.004, Table 3). Logistic regression analysis of these factors
associated with the 1- and 5-year overall survival showed that Six1
protein was the most influential factor for predicting the 1-year
overall survival (OR¼ 5.405, 95% CI 1.427– 20.474, P¼ 0.013)
while pTNM staging was the most important factor for predicting
the 5-year overall survival (OR¼ 12.152, 95% CI 1.652– 89.378,
P¼ 0.004, Table 4).
DISCUSSION
Homeobox transcription factor Six1, which is located at 14q23 of
the chromosome, is involved in the development of many organs
including the brain, ear, eye, muscle and kidney (Relaix and
Buckingham, 1999; Laclef et al, 2003; Xu et al, 2003; Zheng et al,
2003; Ozaki et al, 2004). Alteration of Six1 expression takes place
in human breast and Wilms’ cancer as well as RMS, indicating its
possible contribution in the tumorigenicity of different cancers
(Ford et al, 1998; Li et al, 2002; Yu et al, 2004). Six1 is
Table 1 Summary of Six1 expression in liver tissues from HCC patients
and normal donors
HCC patients
Six1 expression Tumour Nontumour Normal
RNA
Positive 61 (84.7%) 6 (8.3%) 2 (10 %)
Negative 11 (15.3%) 66 (91.7%) 18 (90%)
Protein
Positive 61 (59.2%) 0 (0%) 0 (0 %)
Negative 42 (40.8%) 103 (100%) 20 (100%)
HCC¼ hepatocellular carcinoma.
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Figure 3 Six1 protein expression pattern in HCC patients. Western blot
analysis was performed to exam the Six1 protein in HCC tumour tissues
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Figure 4 RT–PCR amplification and Western blot analysis of Six1 gene
in normal liver tissues. 1–8, liver tissues from different normal donors; C,
positive control.
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overexpressed in 44% of primary tumours and 90% of metastatic
tumours in breast cancer (Ford et al, 1998). Moreover, elevation of
Six1 in human RMS patients is significantly associated with a later
tumour stage (Yu et al, 2004). To investigate whether Six1 is also
deregulated in HCC patients, both mRNA and protein levels of
Six1 were examined in this study. Agreed with other studies, we
found that overexpression of Six1 frequently occurred in tumour
tissues of human HCC patients in terms of about 85% in mRNA
level and 60% in protein level (Table 1). Although overexpression
of Six1 mRNA in tumour tissues of HCC patients was significantly
correlated with their positive Six1 protein expression, the
percentage of Six1 protein overexpression in tumour tissues was
lower than the percentage of Six1 mRNA overexpression. This
phenomenon was also observed in HCC cell lines, in which Hep3B
expressed Six1 mRNA but not Six1 protein (Figure 1). Further-
more, a small portion of HCC nontumour liver tissues (8.3%) and
normal liver tissues (10%) showed positive Six1 mRNA expression
rather than protein expression (Table 1). All these data suggested
that the post-transcriptional regulation of Six1 among HCCs may
be different and Six1 protein level rather than mRNA level is more
likely to reflect its real expression status. In addition, expression of
Six1 protein in liver is probably to be tumour-specific indicated by
the evidence that no Six1 protein was expressed in both normal
liver tissues and HCC nontumour liver tissues (Table 1). The
tumour-specific characteristic of Six1 in HCC may thus provide a
useful implication for therapeutic application of Six1 in HCC by
suppression strategy.
Overexpression of Six1 is potentially related to metastatic status
of breast cancer and RMS (Ford et al, 1998; Yu et al, 2004).
MHCC97H and MHCC97L are human HCC cell lines with the same
genetic background but with different local and distant metastatic
Table 2 Correlation of Six1 protein expression and clinicopathological
features of HCC patients
Six1 protein expression (n)
Clinicopathological
features Number (n) Negative Positive P
Sex
Male 87 35 52 0.792
Female 16 7 9
Age
p55 years 59 25 34 0.703
455 years 44 17 27
pTNM stage
Early stage (I – II) 40 24 16 0.002*
Advanced stage (III – IV) 63 18 45
Venous infiltration
Absent 44 25 19 0.004*
Present 59 17 42
Cirrhosisa
Absent 33 13 20 0.800
Present 69 29 40
Encapsulationa
Absent 48 22 26 0.881
Present 25 11 14
Tumour size
o5 cm 26 13 13 0.268
X5 cm 77 29 48
AFP level
p20 ng ml1 41 20 21 0.179
420 ng ml1 62 22 40
Hepatitis B surface antigena
Negative 16 8 8 0.520
Positive 86 34 52
AFP¼ alpha-fetoprotein; HCC¼ hepatocellular carcinoma; pTNM¼ pathologic
























Six1(−) n = 42
Six1(+) n = 61
Figure 5 Kaplan–Meier overall survival curve of HCC patients in
correlation with Six1 protein expression.
Table 3 Cox proportional hazard regression analysis of Six1 protein expression and clinicopathological parameters in relation to the overall survival of
HCC patients
Univariable analysis Multivariable analysis
HR (95% CI) P HR (95% CI) P
Six1protein
Positive vs negative 1.956 (1.011–3.784) 0.046 1.29 (0.624–2.503) NS
pTNM stage
Advanced vs early 4.952 (2.077–11.808) 0.000 7.698 (1.891–31.33) 0.004
Venous infiltration
Presence vs absence 3.302 (1.572–6.934) 0.002 0.493 (0.136–1.780) NS
AFP level
420 ng ml1 vs p20 ng ml1 3.062 (1032–4.118) 0.04 1.735 (0.783–3.844) NS
AFP¼ alpha-fetoprotein; CI¼ confidence interval; HCC¼ hepatocellular carcinoma; HR¼ hazard ratio; pTNM¼ pathologic tumour-node-metastasis; NS¼ not significant.
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potentials (Li et al, 2001). Orthotopic implantation of MHCC97H
cell into nude mice results in 100% of lung metastasis, whereas
MHCC97L exhibits 40% of lung metastasis (Li et al, 2001). Our
data showed that Six1 protein was only expressed in metastatic
HCC cell lines (MHCC97L and MHCC97H) but not in nonmeta-
static HCC cell lines (Hep3B, Huh7 and PLC). Specific over-
expression of Six1 protein in metastatic HCC cells suggested that
Six1 may be a metastasis-associated oncogene, which may
participate in the process of metastases in HCC. Statistical analysis
of the clinicopathological features of HCC patients revealed that
overexpression of Six1 protein was significantly correlated with
pTNM staging (P¼ 0.002) and venous infiltration (P¼ 0.004).
About 71% of HCC patients recognised at the advanced pTNM
stage (45 of 63) or with venous infiltration (42 of 59) were found to
overexpress Six1 protein, suggesting that Six1 may play an
important role on HCC progression and invasion. Although Six1
protein had not significant association with tumour size
(P¼ 0.268), more than 60% (48 of 77) of HCC patients with
tumours larger than 5 cm showing positive Six1 protein expression
(Table 2), indicating its probable function on tumour progression.
Hepatic resection is one of the major curative options for HCC
patients. Different centres reported to achieve different survival
rates (Llovet et al, 2005). Identification of novel risk markers after
hepatectomy must be beneficial for management of HCC patients
and improvement of their survival. Our result showed that
overexpression of Six1 protein in HCC patients was significantly
associated with poor overall survival after hepatectomy
(P¼ 0.0423, Figure 5), suggesting that Six1 may be a novel marker
related to poor overall survival of HCC patients after hepatectomy.
Although multivariable Cox proportional hazard regression
analysis showed that Six1 protein was not an independent factor
for predicting the overall survival, logistic regression analysis
reflected that Six1 protein was the most influential factor
associated with poor 1-year overall survival (P¼ 0.013, Table 4)
rather than 5-year overall survival (Table 4), proposing that Six1
may be regarded as a predictor for short-term overall survival of
HCC patients after hepatectomy. HCC patients with higher rate of
early-year death after hepatectomy may be caused by higher
malignancy of HCC that pathologically is, in part, determined to be
at the advanced pTNM stage or the presence of venous infiltration.
Overexpression of Six1 protein in HCC patients was determined to
be significantly associated with these malignant factors indicating
the possible role of Six1 on promoting HCC malignancy. Even
though pTNM staging was determined to be the most important
factor in predicting long-term overall survival of HCC patients
after hepatectomy (Tables 3 and 4), assessment of Six1 protein
level of resected tumour tissues of HCC patients may still provide a
valuable index for effective management of HCC patients after
hepatectomy especially during early year.
Up to now, understanding of the mechanism of Six1 in
pathogenesis of cancers is still limited. Overexpression of Six1 in
breast cancer cells can promote the cancer cells to escape from the
G2 cell cycle checkpoint after X-ray irradiation (Ford et al, 1998).
The cell cycle regulatory activity of Six1 in breast cancer is
regulated by casein kinase II which inactivates Six1 through
phosphorylation (Ford et al, 2000). Cyclin A1 is a downstream
effector for Six1 in breast cancer where overexpression of Six1
promotes cyclin A1 expression and subsequently increases cell
proliferation and progression (Coletta et al, 2004). Gene amplifica-
tion of Six1 is a probable mechanism contributing to tumori-
genesis in breast cancer (Reichenberger et al, 2005). Overexpres-
sion of Six1 in RMS cells can boost their pulmonary metastasis
potential, whereas downregulation of Six1 suppresses their
metastatic ability (Yu et al, 2004). Yu et al (2006) also
demonstrated that Six1 potentially activates several oncogenes
including cyclin D1, c-Myc and Ezrin. Moreover, the ability of Six1
in promoting metastasis of RMS requires the function of Ezrin (Yu
et al, 2006). The above research evidences in breast cancer and
RMS provide important clues to clarify the functional roles of Six1
in HCC because different cancers may have different regulatory
mechanisms. In fact, Cyclin A is overexpressed in HCC and its
overexpression is associated with poor survival of HCC patients
(Chao et al, 1998; Ohashi et al, 2001). Casein kinase II shows an
important involvement of transforming growth factor-beta1-
induced HCC (Cavin et al, 2003). The relationship between Six1
and Cyclins as well as casein kinase II in regulating the
tumorigenesis and metastasis of HCC thus need further clarifica-
tion. The specificity of Six1 protein expression in HCC metastatic
cells may also provide a good bridge to study the functions of Six1
involved in metastasis of HCC through suppression strategy such
as using antisense or RNA interference means.
In conclusion, our data indicated that Six1 protein was
specifically and frequently expressed in HCC tumour tissues.
Overexpression of Six1 protein in HCC patients was significantly
associated with advanced pTNM stage and venous infiltration. In
addition, Six1 protein could be a novel marker for predicting the
short-term overall survival of HCC patients after hepatic resection.
Further functional studies are worthwhile to explore the precise
mechanism and eventually develop potential therapies targeting at
Six1 in liver cancer recurrence and metastases.
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Table 4 Logistic regression analysis of Six1 protein and clinicopathological parameters on predicting the 1- and 5-year overall survival of HCC patients
1-year survival 5-year survival
OR (95% CI) P OR (95% CI) P
Six1 protein
Positive vs negative 5.405 (1.427–20.474) 0.013 1.044 (0.401–2.719) NS
pTNM stage
Advanced vs early 2.914 (0.245–34.63) NS 12.152 (1.652–89.378) 0.004
Venous infiltration
Presence vs absence 1.557 (0.155–15.636) NS 0.478 (0.072–3.19) NS
AFP level
420 ng ml1 vs p20 ng ml1 1.754 (0.554–5.552) NS 2.239 (0.846–5.929) NS
AFP¼ alpha-fetoprotein; CI¼ confidence interval; HCC¼ hepatocellular carcinoma; HR¼ hazard ratio; pTNM¼ pathologic tumour-node-metastasis; NS¼ not significant;
OR¼ odd ratio.
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